GPR17 is a synthetic peptide antagonist classified as an orphan drug, primarily developed for its potential in the treatment of metabolic disorders, including type 2 diabetes and obesity, by targeting… Read more
GPR17 is a synthetic peptide antagonist classified as an orphan drug, primarily developed for its potential in the treatment of metabolic disorders, including type 2 diabetes and obesity, by targeting and modulating appetite-regulating pathways. The compounds within this category, which include specific GPR17 impurities, metabolites, and stable isotope-labelled standards, are essential tools for pharmaceutical laboratories and researchers. These reference standards are utilized to facilitate accurate impurity profiling, method validation, and rigorous quality control during the development and manufacturing of the active pharmaceutical ingredient. By providing consistent, high-quality materials, these products support precise analytical testing and ensure the safety and efficacy of the drug throughout the clinical and production lifecycle.